Main Article Content
Abstract
Background: Since December 2019, a new human coronavirus outbreak has spread across various nations, causing numerous cases and deaths. COVID-19 is a disease caused by the brand-new SARS-CoV-2 virus (a brand-new stress of coronavirus). Wuhan, Hubei Province, People's Republic of China, is a ten-million-person metropolis. The cornerstone and most important management strategy for clinical management of COVID-19 remains early adjunct care and monitoring, which includes O2 supplementation, organ support, and interference of complications, particularly acute respiratory distress syndrome, organ failure, and secondary health facility infections.
Conclusion: COVID-19 is a pandemic that is causing an increase in the number of infections and deaths. In response to the epidemic, many pharmacologic medicines are being utilized off-label or evaluated for therapy around the world. Antiviral medications (eight drugs), antimalarial drugs (two drugs), systemic corticosteroids (five drugs), and immune-based therapy are the four primary groups of drugs suggested in treatment guidelines around the world (seven drugs). There is a lot of difference between these rules in general. These mostly dealt with drug indications, types of pharmaceuticals, dose regimens, treatment periods, and drug safety in various patient groups
Keywords
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.